Submitted:
29 September 2025
Posted:
30 September 2025
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and Methods
Subjects and Ethical Statement
Audiometry and Timeline of Experiments
Statistical Evaluation
3. Results
3.1. Study Design
3.2. Database
3.3. Efficacy of LINTS
3.4. Exemplary Case Reports
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| AM | Amplitude modulation |
| CBT | Cognitive behavioral therapy |
| DCN | Dorsal cochlear nucleus |
| HA | Hearing aid |
| HL | Hearing loss |
| LIN | Low intensity noise |
| LINTS | Low intensity noise tinnitus suppression |
| Mini-TQ12 | Mini tinnitus questionnaire with 12 items |
| NB | Narrow band noise |
| PT | Placebo-plus treatment patients |
| SR | Stochastic resonance |
| TF | Tinnitus frequency (also: tinnitus pitch) |
| THQ | Tinnitus health questionnaire |
| TL | Tinnitus loudness |
| TSCHQ | Tinnitus sample case history questionnaire |
| TO | Treatment only patients |
| WB | Wide band noise |
| WN | White noise |
References
- Di Stadio, A.; Dipietro, L.; Ricci, G.; Della Volpe, A.; Minni, A.; Greco, A.; De Vincentiis, M.; Ralli, M. Hearing loss, tinnitus, hyperacusis, and diplacusis in professional musicians: a systematic review. International journal of environmental research and public health 2018, 15, 2120. [CrossRef]
- Nelson, J.J.; Chen, K. The relationship of tinnitus, hyperacusis, and hearing loss. Ear, nose & throat journal 2004, 83, 472-476. [CrossRef]
- Savastano, M. Tinnitus with or without hearing loss: are its characteristics different? Eur Arch Otorhinolaryngol 2008, 265, 1295-1300. [CrossRef]
- Schaette, R.; McAlpine, D. Tinnitus with a normal audiogram: physiological evidence for hidden hearing loss and computational model. J Neurosci 2011, 31, 13452-13457. [CrossRef]
- Hebert, S.; Canlon, B.; Hasson, D.; Magnusson Hanson, L.L.; Westerlund, H.; Theorell, T. Tinnitus severity is reduced with reduction of depressive mood–a prospective population study in Sweden. PloS one 2012, 7, e37733.
- Lewis, J.E.; Stephens, S.D.; McKenna, L. Tinnitus and suicide. Clin Otolaryngol Allied Sci 1994, 19, 50-54.
- Tziridis, K.; Friedrich, J.; Brueggemann, P.; Mazurek, B.; Schulze, H. Estimation of Tinnitus-Related Socioeconomic Costs in Germany. Int J Environ Res Public Health 2022, 19. [CrossRef]
- Maes, I.H.; Cima, R.F.; Vlaeyen, J.W.; Anteunis, L.J.; Joore, M.A. Tinnitus: a cost study. Ear and hearing 2013, 34, 508-514. [CrossRef]
- Mazurek, B.; Hesse, G.; Sattel, H.; Kratzsch, V.; Lahmann, C.; Dobel, C. S3 Guideline: Chronic Tinnitus: German Society for Otorhinolaryngology, Head and Neck Surgery e. V.(DGHNO-KHC). Hno 2022, 70, 795-827. [CrossRef]
- Jalilvand, H.; Pourbakht, A.; Haghani, H. Hearing aid or tinnitus masker: which one is the best treatment for blast-induced tinnitus? The results of a long-term study on 974 patients. Audiology and Neurotology 2015, 20, 195-201.
- Kil, J.; Harruff, E.E.; Longenecker, R.J. Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing Research 2022, 413, 108209. [CrossRef]
- Kleinjung, T.; Langguth, B. Avenue for Future Tinnitus Treatments. Otolaryngologic Clinics of North America 2020, 53, 667-683. [CrossRef]
- Okamoto, H.; Stracke, H.; Stoll, W.; Pantev, C. Listening to tailor-made notched music reduces tinnitus loudness and tinnitus-related auditory cortex activity. Proc Natl Acad Sci U S A 2010, 107, 1207-1210. [CrossRef]
- Tass, P.A.; Adamchic, I.; Freund, H.-J.; von Stackelberg, T.; Hauptmann, C. Counteracting tinnitus by acoustic coordinated reset neuromodulation. Restorative neurology and neuroscience 2012, 30, 137-159.
- Tyler, R.; Cacace, A.; Stocking, C.; Tarver, B.; Engineer, N.; Martin, J.; Deshpande, A.; Stecker, N.; Pereira, M.; Kilgard, M. Vagus nerve stimulation paired with tones for the treatment of tinnitus: a prospective randomized double-blind controlled pilot study in humans. Scientific reports 2017, 7, 11960.
- Stein, A.; Wunderlich, R.; Lau, P.; Engell, A.; Wollbrink, A.; Shaykevich, A.; Kuhn, J.-T.; Holling, H.; Rudack, C.; Pantev, C. Clinical trial on tonal tinnitus with tailor-made notched music training. BMC neurology 2016, 16, 38.
- Távora-Vieira, D.; Marino, R.; Krishnaswamy, J.; Kuthbutheen, J.; Rajan, G.P. Cochlear implantation for unilateral deafness with and without tinnitus: a case series. The Laryngoscope 2013, 123, 1251-1255.
- Krauss, P.; Tziridis, K.; Metzner, C.; Schilling, A.; Hoppe, U.; Schulze, H. Stochastic Resonance Controlled Upregulation of Internal Noise after Hearing Loss as a Putative Cause of Tinnitus-Related Neuronal Hyperactivity. Front Neurosci 2016, 10, 597. [CrossRef]
- Krauss, P.; Metzner, C.; Schilling, A.; Schutz, C.; Tziridis, K.; Fabry, B.; Schulze, H. Adaptive stochastic resonance for unknown and variable input signals. Sci Rep 2017, 7, 2450. [CrossRef]
- Schilling, A.; Sedley, W.; Gerum, R.; Metzner, C.; Tziridis, K.; Maier, A.; Schulze, H.; Zeng, F.-G.; Friston, K.J.; Krauss, P. Predictive coding and stochastic resonance as fundamental principles of auditory phantom perception. Brain 2023, 146, 4809-4825.
- Tziridis, K.; Forster, J.; Buchheidt-Dorfler, I.; Krauss, P.; Schilling, A.; Wendler, O.; Sterna, E.; Schulze, H. Tinnitus development is associated with synaptopathy of inner hair cells in Mongolian gerbils. Eur J Neurosci 2021, 54, 4768-4780. [CrossRef]
- Kujawa, S.G.; Liberman, M.C. Adding insult to injury: cochlear nerve degeneration after "temporary" noise-induced hearing loss. J Neurosci 2009, 29, 14077-14085. [CrossRef]
- Chen, F.; Zhao, F.; Mahafza, N.; Lu, W. Detecting noise-induced cochlear synaptopathy by auditory brainstem response in tinnitus patients with normal hearing thresholds: A meta-analysis. Frontiers in Neuroscience 2021, 15, 778197. [CrossRef]
- Schulze, H.; Schilling, A.; Krauss, P.; Tziridis, K. The Erlangen model of tinnitus development-New perspective and treatment strategy. HNO 2023, 71, 662-668.
- Shore, S.E.; Zhou, J. Somatosensory influence on the cochlear nucleus and beyond. Hearing research 2006, 216, 90-99. [CrossRef]
- Chen, M.; Min, S.; Zhang, C.; Hu, X.; Li, S. Using Extracochlear Multichannel Electrical Stimulation to Relieve Tinnitus and Reverse Tinnitus-Related Auditory-Somatosensory Plasticity in the Cochlear Nucleus. Neuromodulation: Technology at the Neural Interface 2022, 25, 1338-1350.
- Schilling, A.; Krauss, P.; Hannemann, R.; Schulze, H.; Tziridis, K. Reduktion der Tinnituslautstärke. HNO 2020, 69, 891-898. [CrossRef]
- Tziridis, K.; Brunner, S.; Schilling, A.; Krauss, P.; Schulze, H. Spectrally Matched Near-Threshold Noise for Subjective Tinnitus Loudness Attenuation Based on Stochastic Resonance. Front Neurosci 2022, 16, 831581. [CrossRef]
- Hiller, W.; Goebel, G. Rapid assessment of tinnitus-related psychological distress using the Mini-TQ. Int J Audiol 2004, 43, 600-604.
- Goebel, G.; Hiller, W. Tinnitus-Fragebogen (TF). Standardinstrument zur Graduierung des Tinnitusschweregrades. Erbebnisse einer Multicenterstudie mit dem Tinnitus-Fragebogen (TF). HNO. Hals-, Nasen-, Ohrenärzte 1994, 42, 166-172.
- Langguth, B.; Goodey, R.; Azevedo, A.; Bjorne, A.; Cacace, A.; Crocetti, A.; Del Bo, L.; De Ridder, D.; Diges, I.; Elbert, T. Consensus for tinnitus patient assessment and treatment outcome measurement: Tinnitus Research Initiative meeting, Regensburg, July 2006. Progress in brain research 2007, 166, 525-536.
- Schulze, H.; Tziridis, K. Is phase locking crucial to improve hearing thresholds in tinnitus patients? Eur J Neurosci 2023, 58, 2361-2366. [CrossRef]
- Hazell, J.; Wood, S. Tinnitus masking-a significant contribution to tinnitus management. British journal of audiology 1981, 15, 223-230. [CrossRef]






| group | (sub-)score | timepoint | chi² test results | score means | standard deviation |
|---|---|---|---|---|---|
| treatment only patient group (TO) | emotional and cognitive distress | 2 weeks treatment | (N=45. df=2)=10.47 p=0.005 |
-1.33 | 4.82 |
| 4 weeks treatment | -2.87 | 4.21 | |||
| 4 weeks post treatment | -1.8 | 4.63 | |||
| intrusiveness | 2 weeks treatment | (N=45. df=2)=39.85 p<0.001 |
-0.62 | 2.57 | |
| 4 weeks treatment | -3.36 | 2.45 | |||
| 4 weeks post treatment | -0.60 | 2.21 | |||
| auditory perceptual difficulties | 2 weeks treatment | (N=45. df=2)=5.15 p=0.076 |
-0.07 | 1.74 | |
| 4 weeks treatment | -0.36 | 1.88 | |||
| 4 weeks post treatment | -0.18 | 2.24 | |||
| sleep disturbances | 2 weeks treatment | (N=45. df=2)=0.57 p=0.75 |
-0.42 | 1.14 | |
| 4 weeks treatment | -0.40 | 1.32 | |||
| 4 weeks post treatment | -0.49 | 0.97 | |||
| somatic complains | 2 weeks treatment | (N=45. df=2)=0.64 p=0.73 |
-0.29 | 1.12 | |
| 4 weeks treatment | -0.36 | 1.13 | |||
| 4 weeks post treatment | -0.47 | 1.12 | |||
| global tinnitus severity | 2 weeks treatment | (N=45. df=2)=6.73 p=0.035 |
-2.96 | 8.21 | |
| 4 weeks treatment | -4.96 | 6.65 | |||
| 4 weeks post treatment | -3.2 | 7.59 | |||
| Placebo plus treatment patient group (PT) | emotional and cognitive distress | 2 weeks placebo | (N=20. df=3)=2.16 p=0.54 |
-0.40 | 3.86 |
| 2 weeks treatment | -1.20 | 2.44 | |||
| 4 weeks treatment | -1.65 | 2.35 | |||
| 4 weeks post treatment | -1.35 | 1.90 | |||
| intrusiveness | 2 weeks placebo | (N=20. df=3)=18.75 p<0.001 |
-0.50 | 2.09 | |
| 2 weeks treatment | -2.05 | 2.39 | |||
| 4 weeks treatment | 0.05 | 2.94 | |||
| 4 weeks post treatment | 0.55 | 1.70 | |||
| auditory perceptual difficulties | 2 weeks placebo | (N=20. df=3)=1.00 p=0.80 |
0.35 | 1.18 | |
| 2 weeks treatment | 0.10 | 1.71 | |||
| 4 weeks treatment | -0.25 | 1.71 | |||
| 4 weeks post treatment | -0.05 | 1.82 | |||
| sleep disturbances | 2 weeks placebo | (N=20. Df=3)=2.58 p=0.46 |
0.10 | 1.21 | |
| 2 weeks treatment | 0.35 | 1.60 | |||
| 4 weeks treatment | 0.35 | 1.27 | |||
| 4 weeks post treatment | 0.70 | 2.27 | |||
| somatic complains | 2 weeks placebo | (N=20. df=3)=7.68 p=0.053 |
0.65 | 1.84 | |
| 2 weeks treatment | 0.20 | 0.83 | |||
| 4 weeks treatment | -0.15 | 0.67 | |||
| 4 weeks post treatment | 0.10 | 0.79 | |||
| global tinnitus severity | 2 weeks placebo | (N=20. df=3)=3.96 p=0.27 |
0.55 | 4.39 | |
| 2 weeks treatment | -0.55 | 5.87 | |||
| 4 weeks treatment | -2.35 | 5.84 | |||
| 4 weeks post treatment | -1.75 | 5.00 |
| group | (sub-)score | timepoint | Wilcoxon test results | Median (25%, 75%) |
|---|---|---|---|---|
| treatment only patient group (TO) | emotional and cognitive distress |
2 weeks treatment | T=252.5; Z=2.12 p=0.03 |
-1 (-3, 1) |
| 4 weeks treatment | T=136.5; Z=3.68 p<0.001 |
-2 (-4, 0) | ||
| 4 weeks post treatment | T=250; Z=2.34 p=0.02 |
-1 (-4, 1) | ||
| intrusiveness | 2 weeks treatment | T=331; Z=1.29 p=0.20 |
-1 (-2, 1) | |
| 4 weeks treatment | T=29; Z=5.51 p<0.001 |
-3 (-5, -2) | ||
| 4 weeks post treatment | T=214.5; Z=1.86 p=0.06 |
0 (-2, 1) | ||
| auditory perceptual difficulties |
2 weeks treatment | T=250.5; Z=0.25 p=0.80 |
0 (-1, 1) | |
| 4 weeks treatment | T=245; Z=1.38 p=0.17 |
0 (-1, 1) | ||
| 4 weeks post treatment | T=216; Z=0.34 p=0.73 |
0 (-1, 1) | ||
| sleep disturbances | 2 weeks treatment | T=138; Z=1.94 p=0.05 |
0 (-1, 0) | |
| 4 weeks treatment | T=131; Z=1.87 p=0.06 |
0 (-1, 0) | ||
| 4 weeks post treatment | T=47.5; Z=2.56 p=0.01 |
0 (-1, 0) | ||
| somatic complains | 2 weeks treatment | T=61; Z=2.34 p=0.02 |
0 (-1, 0) | |
| 4 weeks treatment | T=56; Z=2.07 p=0.04 |
0 (-1, 0) | ||
| 4 weeks post treatment | T=44; Z=1.81 p=0.07 |
0 (-1, 0) | ||
| global tinnitus severity | 2 weeks treatment | T=267; Z=2.49 p=0.01 |
-3 (-7, 2) | |
| 4 weeks treatment | T=120.5; Z=4.37 p<0.001 |
-4 (-9, 0) | ||
| 4 weeks post treatment | T=285.5; Z=2.62 p=0.009 |
-3 (-8, 1) | ||
| Placebo plus treatment patient group (PT) | emotional and cognitive distress |
2 weeks placebo | T=64; Z=1.25 p=0.21 |
-0.5 (-3, 1.5) |
| 2 weeks treatment | T=28; Z=2.30 p=0.02 |
-1 (-3, 0) | ||
| 4 weeks treatment | T=31.5; Z=2.56 p=0.01 |
-2 (-2, -1) | ||
| 4 weeks post treatment | T=16.5; Z=2.66 p=0.008 |
-0.5 (-3, 0) | ||
| intrusiveness | 2 weeks placebo | T=65; Z=0.89 p=0.37 |
0 (-1, 1) | |
| 2 weeks treatment | T=45; Z=0.85 p=0.39 |
0 (0,1) | ||
| 4 weeks treatment | T=13; Z=3.16 p=0.002 |
-2 (-4, 0) | ||
| 4 weeks post treatment | T=85; Z=0.75 p=0.46 |
-0.5 (-2, 1) | ||
| auditory perceptual difficulties |
2 weeks placebo | T=65; Z=0.54 p=0.59 |
0 (-1, 1) | |
| 2 weeks treatment | T=63.5; Z=0.23 p=0.82 |
0 (-1, 1) | ||
| 4 weeks treatment | T=49.5; Z=0.96 p=0.34 |
0 (-2, 1) | ||
| 4 weeks post treatment | T=69; Z=0.36 p=0.72 |
0 (-1, 1) | ||
| sleep disturbances | 2 weeks placebo | T=27.5; Z=1.26 p=0.21 |
0 (0, 1) | |
| 2 weeks treatment | T=20; Z=1.16 p=0.25 |
0 (0, 1) | ||
| 4 weeks treatment | T=33; Z=0.47 p=0.64 |
0 (-1, 0) | ||
| 4 weeks post treatment | T=29; Z=0.36 p=0.72 |
0 (-1, 0) | ||
| somatic complains | 2 weeks placebo | T=12; Z=1.58 p=0.11 |
0 (0, 1) | |
| 2 weeks treatment | T=10.5; Z=1.42 p=0.16 |
0 (0, 1) | ||
| 4 weeks treatment | T=6; Z=0.94 p=0.35 |
0 (0, 0) | ||
| 4 weeks post treatment | T=8; Z=1.01 p=0.31 |
0 (0, 0) | ||
| global tinnitus severity | 2 weeks placebo | T=106.5; Z=0.31 p=0.75 |
0.5 (-2.5, 2.5) | |
| 2 weeks treatment | T=83; Z=0.11 p=0.91 |
0 (-3, 3) | ||
| 4 weeks treatment | T=55; Z=1.87 p=0.06 |
-3 (-5, 0) | ||
| 4 weeks post treatment | T=88; Z=1.25 p=0.21 |
-1 (-3,5, 2) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).